Based on the Abbott Laboratories stock forecast from 17 analysts, the average analyst target price for Abbott Laboratories is USD 128.57 over the next 12 months. Abbott Laboratories’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Abbott Laboratories is Slightly Bullish , which is based on 8 positive signals and 5 negative signals. At the last closing, Abbott Laboratories’s stock price was USD 115.90. Abbott Laboratories’s stock price has changed by -0.59% over the past week, -1.63% over the past month and +15.60% over the last year.
No recent analyst target price found for Abbott Laboratories
No recent average analyst rating found for Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provide...Read More
N/A
N/A
114,000
N/A
USD
USA
Adjusted Closing Price for Abbott Laboratories (ABT)
Loading...
Unadjusted Closing Price for Abbott Laboratories (ABT)
Loading...
Share Trading Volume for Abbott Laboratories Shares
Loading...
Compare Performance of Abbott Laboratories Shares
Symbol
Capital Gain
Dividend Return
Total Return
Loading...
Loading...
Technical Indicators for ABT
Assets
Top Holdings
N/A
Top Sectors
Top Regions
Stocks Similar To Abbott Laboratories (Sector: Medical Devices )
Frequently Asked Questions About Abbott Laboratories (ABT) Stock
Based on ratings from 17 analysts Abbott Laboratories's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 19 buy, sell and 4 hold ratings.
ABT stock's dividend yield is 1.90%.
Our analysis grades ABT stock's dividend yield at D+. This means that ABT stock's dividend yield is above 67% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this ABT may be a average dividend stock for its sector.
Based on targets from 17 analysts, the average taret price for ABT is USD 128.57 over the next 12 months. The maximum analyst target price is USD 149 while the minimum anlayst target price is USD 117.
ABT stock's Price/Earning ratio is 35.23.
Our analysis grades ABT stock's Price / Earning ratio at C. This means that ABT stock's Price/Earning ratio is above 26% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this ABT may be undervalued for its sector.
The last closing price of ABT's stock was USD 115.90.
The most recent market capitalization for ABT is USD 201.02B.
Based on targets from 17 analysts, the average taret price for ABT is projected at USD 128.57 over the next 12 months.
This means that ABT's stock price may go up by +10.93% over the next 12 months.
We can't find any ETFs which contains Abbott Laboratories's stock.
As per our most recent records Abbott Laboratories has 114,000 Employees.
Sorry we do not have any infomation available on Abbott Laboratories's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Abbott Laboratories (ABT) Stock
Based on ratings from 17 analysts Abbott Laboratories's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 19 buy, sell and 4 hold ratings.
ABT stock's dividend yield is 1.90%.
Our analysis grades ABT stock's dividend yield at D+. This means that ABT stock's dividend yield is above 67% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this ABT may be a average dividend stock for its sector.
Based on targets from 17 analysts, the average taret price for ABT is USD 128.57 over the next 12 months. The maximum analyst target price is USD 149 while the minimum anlayst target price is USD 117.
ABT stock's Price/Earning ratio is 35.23.
Our analysis grades ABT stock's Price / Earning ratio at C. This means that ABT stock's Price/Earning ratio is above 26% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this ABT may be undervalued for its sector.
The last closing price of ABT's stock was USD 115.90.
The most recent market capitalization for ABT is USD 201.02B.
Based on targets from 17 analysts, the average taret price for ABT is projected at USD 128.57 over the next 12 months.
This means that ABT's stock price may go up by +10.93% over the next 12 months.
We can't find any ETFs which contains Abbott Laboratories's stock.
As per our most recent records Abbott Laboratories has 114,000 Employees.
Sorry we do not have any infomation available on Abbott Laboratories's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ABT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
